On Monday, Purple Biotech Ltd (NASDAQ:PPBT) reported the final results from the randomized Phase 2 study of its lead oncology ...

Researchers at Kumamoto University have discovered a monoclonal antibody capable of neutralizing a wide range of SARS-CoV-2 ...

Matias Sanchez, MD, assistant professor in the Department of Medicine at the University of Illinois Chicago, discussed recent advancements in multiple myeloma treatment, including the potential of ...

Final data demonstrate CM24 in combination with nivolumab and Nal-IRI/5FU/LV chemotherapy clear and consistent improvement ...

Yesintek, a monoclonal antibody, is approved for the treatment of Crohn's disease, olcerative colitis, plaque psoriasis, and ...

One of the major stories in multiple myeloma in 2024 was the comeback of belantamab mafodotin (Blenrep) after it had been ...

In today's trade, several stocks, including Eicher Motors, Tata Motors, Hyundai, and Cipla, are expected to be in focus due ...

Collaboration with Janssen aims to fast-track the launch and enhance accessibility to YESINTEK for patients in need.

The biosimilar is approved for the treatment of Crohn’s disease, Ulcerative Colitis, Plaque Psoriasis and Psoriatic Arthritis ...

YESINTEK works by targeting specific proteins that contribute to inflammation, offering a new treatment option for patients ...

Kumamoto University researchers have identified a powerful antibody that can neutralize a wide range of SARS-CoV-2 variants, ...

A decade after the discovery of CALR, the results are the first for a possible therapy for CALR-mutated MPNs to reach the ...